CVRx (NASDAQ:CVRX) Posts Earnings Results, Beats Expectations By $0.01 EPS

CVRx (NASDAQ:CVRX) posted its earnings results on Wednesday. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.01, FiscalAI reports. The firm had revenue of $14.69 million for the quarter, compared to analyst estimates of $14.16 million. CVRx had a negative return on equity of 79.31% and a negative net margin of 95.61%. CVRx updated its Q4 2025 guidance to EPS and its FY 2025 guidance to EPS.

CVRx Stock Performance

NASDAQ CVRX traded up $0.24 on Thursday, hitting $10.03. 517,490 shares of the stock traded hands, compared to its average volume of 291,241. The firm has a market capitalization of $262.25 million, a price-to-earnings ratio of -4.78 and a beta of 1.28. The business’s fifty day moving average is $8.66 and its two-hundred day moving average is $7.51. CVRx has a 12 month low of $4.30 and a 12 month high of $18.55. The company has a debt-to-equity ratio of 0.85, a quick ratio of 10.78 and a current ratio of 11.99.

Analysts Set New Price Targets

CVRX has been the subject of several recent research reports. Canaccord Genuity Group upped their price objective on CVRx from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Thursday. Cantor Fitzgerald raised their price objective on CVRx from $11.00 to $13.00 and gave the company an “overweight” rating in a report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CVRx in a report on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $13.17.

Institutional Investors Weigh In On CVRx

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Balyasny Asset Management L.P. increased its stake in CVRx by 65.5% in the second quarter. Balyasny Asset Management L.P. now owns 674,685 shares of the company’s stock valued at $3,967,000 after acquiring an additional 267,063 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of CVRx by 7.6% during the second quarter. Bank of America Corp DE now owns 89,049 shares of the company’s stock valued at $524,000 after purchasing an additional 6,312 shares during the last quarter. Cresset Asset Management LLC lifted its holdings in shares of CVRx by 3.5% during the second quarter. Cresset Asset Management LLC now owns 53,542 shares of the company’s stock valued at $315,000 after purchasing an additional 1,823 shares during the last quarter. Marshall Wace LLP increased its position in shares of CVRx by 238.1% during the second quarter. Marshall Wace LLP now owns 350,080 shares of the company’s stock valued at $2,058,000 after acquiring an additional 246,548 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in CVRx in the 2nd quarter worth approximately $155,000. Hedge funds and other institutional investors own 75.27% of the company’s stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.